Literature DB >> 6102123

Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C.

T Kojima, M Hashida, S Muranishi, H Sezaki.   

Abstract

A high molecular weight derivative of mitomycin C (MMC), mitomycin C-dextran conjugate (MMC-D) has been synthesized and its biological and pharmacological properties investigated. MMC is released from MMC-D in vitro with a half-life of 24 h. After intraperitoneal injection of MMC-D, free MMC could be detected in plasma and urine of mouse for 5--8 h, while MMC administered as a free form was eliminated rapidly. After MMC-D, given to mice bearing Ehrlich ascites carcinoma or B16 melanoma there was a reduction in toxicitst that the high molecular weight MMC-dextran derivative is a kind of pro-drug which persists in the body giving a sustained release of free MMC thus significantly increasing the antitumour activity of the parent drug.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6102123     DOI： 10.1111/j.2042-7158.1980.tb12840.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


  9 in total

1.  Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver.

Authors:  K Nishida; K Mihara; T Takino; S Nakane; Y Takakura; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

Review 2.  Nanoparticles containing insoluble drug for cancer therapy.

Authors:  Shutao Guo; Leaf Huang
Journal:  Biotechnol Adv       Date:  2013-10-08       Impact factor: 14.227

3.  Disposition and tumor localization of mitomycin C-dextran conjugates in mice.

Authors:  Y Takakura; A Takagi; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1987-08       Impact factor: 4.200

4.  Disposition characteristics of macromolecules in tumor-bearing mice.

Authors:  Y Takakura; T Fujita; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

5.  'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics.

Authors:  Sampath C Abeylath; Mansoor M Amiji
Journal:  Bioorg Med Chem       Date:  2011-09-17       Impact factor: 3.641

6.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.

Authors:  R Duncan; P Kopecková; J Strohalm; I C Hume; J B Lloyd; J Kopecek
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

7.  Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate.

Authors:  A Noguchi; T Takahashi; T Yamaguchi; K Kitamura; Y Takakura; M Hashida; H Sezaki
Journal:  Jpn J Cancer Res       Date:  1991-02

8.  Characterization of Serine Protease Inhibitor from Solanum tuberosum Conjugated to Soluble Dextran and Particle Carriers.

Authors:  Erika Billinger; Shusheng Zuo; Gunnar Johansson
Journal:  ACS Omega       Date:  2019-10-25

9.  Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury.

Authors:  Lei Qi; Haiyan Jiang; Xiaohui Cui; Guiwen Liang; Ming Gao; Zhongwei Huang; Qinghua Xi
Journal:  Oncotarget       Date:  2017-09-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.